RayStation® will be extended to include treatment planning for the TomoTherapy® and CyberKnife® Systems

RaySearch Laboratories AB (publ) (NASDAQ OMX Stockholm: RAY B) and Accuray Incorporated (Nasdaq: ARAY) announced today that they have expanded on their existing relationship with the signing of a new long-term collaboration agreement, which will lead to the integration of treatment planning support for the TomoTherapy® and CyberKnife® Systems in the RayStation® treatment planning system (TPS). RayStation is one of the most advanced independent treatment planning systems available and will provide an ideal complement to the unique Accuray treatment delivery systems, enabling customers to choose the delivery technology that will best meet their needs. Accuray and RaySearch previously announced a long-term collaboration regarding the RayCare® oncology information system.

“This agreement marks an important progression in our partnership with RaySearch. We believe the integration of their industry-leading TPS along with our innovative treatment delivery systems will enable clinicians to further optimize their experience and use of Accuray technology long-term,” said Joshua H. Levine, president and chief executive officer of Accuray. “Our goal is to maximize the clinical effectiveness of our Systems and enhance the ease with which they integrate within the radiation oncology department. We are pursuing multiple paths to achieve this result, including this agreement with RaySearch, which will provide both flexibility and enhanced options for our customers.”

Under the contract, Accuray will have the opportunity to offer RayStation to clinicians who use the TomoTherapy and CyberKnife System product portfolios. Current RayStation users report that the software provides multiple benefits including advanced treatment planning tools, leading workflow support and an excellent user experience, all of which enhance treatment delivery flexibility within a radiation oncology department.

Accuray has an installed base of more than 500 TomoTherapy Systems and more than 300 CyberKnife Systems worldwide. Treatment planning support for TomoTherapy Systems in RayStation is targeted for release during 2016 and support for CyberKnife Systems for release during 2017.

“This agreement with Accuray enables us to expand our relationship with a like-minded company committed to improving the way radiation therapy is delivered,” said Johan Löf, president and chief executive officer of RaySearch Laboratories AB (publ). “For the first time ever, treatment planning for both of the Accuray systems as well as conventional linear accelerators will be available in one integrated treatment planning system. This integration alone will entail significant gains in efficiency for clinics that have several machine types. Additionally, we see that many of RayStation’s unique strengths are exceptionally well suited to the Accuray systems. In summary, we think that this collaboration will strengthen both RayStation’s and the Accuray systems’ competitiveness.”

About the CyberKnife and TomoTherapy Systems
The Accuray CyberKnife M6™ Series and TomoTherapy H™ Series treatment solutions cover the entire spectrum of radiation therapy needs. The CyberKnife M6 Series enables precise, high-quality, high-dose distributions to be confidently delivered to the patient with extreme accuracy over a minimum number of treatments, reducing side effects and preserving patients' quality of life. The CyberKnife System is the only robotic full-body radiosurgery system available today. The TomoTherapy H Series efficiently enables physicians to customize treatment plans for the entire range of radiation therapy patients and disease types. Its innovative design enables treatment plans to be delivered with integrated, daily CT image guidance, enhancing accuracy and delivering highly precise, intensity-modulated radiation for optimal sparing of healthy tissue and critical structures.

Further information on Accuray, the CyberKnife® and TomoTherapy® Systems is available at www.accuray.com.

About Accuray
Accuray Incorporated (Nasdaq: ARAY) is a radiation oncology company that develops, manufactures and sells precise, innovative tumor treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. The company's leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments.

Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to future growth, market success, adoption of our new products, clinical benefits of our technologies, patient outcomes and Accuray’s leadership position in radiation oncology innovation and technologies. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations, including but not limited to the risks detailed under the heading “Risk Factors” in the company’s report on Form 10-K, filed on August 28, 2015, and the company’s other filings with the SEC.

Forward-looking statements speak only as of the date the statements are made and are based on information available to Accuray at the time those statements are made and/or management’s good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.

About RayStation®
RayStation® integrates all RaySearch’s advanced treatment planning solutions into an innovative and flexible treatment planning system. It combines unique features such as multi-criteria optimization tools with full support for 4D adaptive radiation therapy. It also includes functionality such as RaySearch’s market-leading algorithms for IMRT and VMAT optimization and highly accurate dose engines for photon, electron, proton and carbon ion therapy. The system is built on the latest software architecture and has a graphical user interface offering state-of-the-art usability.

About RaySearch
RaySearch Laboratories AB (publ) is a medical technology company that develops advanced software solutions for improved radiation therapy of cancer. RaySearch markets the RayStation® treatment planning system to clinics all over the world. In addition, RaySearch’s products are distributed through licensing agreements with leading medical technology companies. RaySearch’s software solutions are used by over 2,500 clinics in more than 65 countries. RaySearch was founded in 2000 as a spin-off from Karolinska Institutet in Stockholm and the company is listed in the Small Cap segment on NASDAQ OMX Stockholm.

For more information about RaySearch, visit www.raysearchlabs.com.

For further information please contact:
RaySearch Laboratories AB (publ)
Johan Löf, President and CEO, RaySearch Laboratories AB (publ)
Telephone: +46 (0)8-510 530 00
johan.lof@raysearchlabs.com

Accuray
Investors:
Chris Dailey
Investor Relations, EVC Group
+1 (646) 445-4801
Cdailey@evcgroup.com

Media:
Beth Kaplan
Public Relations Director, Accuray
+1 (408) 789-4426
bkaplan@accuray.com

Kirsten Fallon
MSLGROUP in Boston
+1 (781) 684-0770
Kirsten.Fallon@MSLGROUP.com